By Will Feuer


Gilead Sciences said a Phase 3 trial testing Trodelvy in certain lung cancer patients failed to improve overall survival, results that sent shares sharply lower.

Gilead agreed in 2022 to buy Trodelvy-maker Immunomedics for $21 billion.

In the Phase 3 trial, Gilead is evaluating Trodelvy versus docetaxel in patients with metastatic or advanced non-small cell lung cancer that had progressed on or after chemotherapy and checkpoint inhibitor therapy.

Gilead said it did observe a numerical improvement in overall survival favoring Trodelvy, but that the results didn't meet the threshold of the primary endpoint.

Gilead said it plans to discuss the trial results with regulators, and present the data at an upcoming medical meeting.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

01-22-24 0902ET